Spartalizumab (anti-PD-1)

Catalog No.A2017        Batch: A201703

Print

Technical Data

CAS No. 1935694-88-4
Formulation PBS buffer, pH 7.2
Isotype Human IgG4
Source CHO cells
Storage
(From the date of receipt)
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Purity 99%
Protein concentration 4.54 mg/ml
Endotoxin Level <1 EU/mg

Biological Activity

Description Spartalizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1, MW: 145.8 KD.
Targets
PD-1 [1]
In vivo In phase 1/2 studies, PDR001 has a manageable safety profile and preliminary antitumor activity in advanced solid tumors[1].

Selleck's Spartalizumab (anti-PD-1) has been cited by 1 publication

Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α. [ Elife, 2020, 9] PubMed: 32091388

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.